ZTS Stock Analysis — Zoetis
Sector: Healthcare
AI Verdict
Zoetis trades at 15.9x next year's earnings with a -22.4% EPS decline expected, so you're getting a cheap price but only if its regulatory and distribution moat can halt the earnings slide.
Competitive Moat
Zoetis develops and manufactures proprietary animal health medicines and vaccines, with deep relationships across veterinary clinics and livestock producers. Its moat comes from regulatory barriers, a broad patent-protected portfolio, and entrenched distribution in a highly specialized market.
Summary
Zoetis is flashing an extreme RSI of 5.4, signaling one of the most oversold conditions in the market.
Where It Stands
Shares are down -54.48% over the past year, trade at 15.9x next year's earnings (well below the healthcare sector median of 22x), and the RSI of 5.4 is deeply oversold.
Key Metrics
- RSI: 5.4 — Oversold
- Trailing P/E: 12.3x
- Forward P/E: 15.9x
- Earnings Growth: -0.2%
- Revenue Growth: +0.0%
- Market Cap: $31.1B
- Dividend Yield: 0.02%
- 1-Year Return: -54.48%
- 52-Week High: $172.23
- 52-Week Low: $72.38
Analyst Consensus
16 Buy · 9 Hold · 0 Sell (25 analysts)
Bull Case
At 15.9x forward earnings, you're paying a historically low multiple for a business with entrenched veterinary relationships and regulatory barriers, if it can stabilize after this year's -22.4% expected EPS drop.
Bear Case
With forward EPS expected to fall -22.4% and a trailing P/E of just 12.3x, even a modest further de-rating to 10x would cut another ~19% off the stock price.
Catalyst to Watch
Watch for any signs of stabilization or recovery in earnings guidance — a less negative EPS outlook could trigger a sharp rebound from these oversold levels.